Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

被引:52
作者
Deshpande, Devyani
Srivastava, Shashikant
Meek, Claudia [2 ]
Leff, Richard [2 ]
Gumbo, Tawanda [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Med, Div Infect Dis, Dallas, TX 75390 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dallas, TX USA
关键词
IN-VITRO; DRUG-RESISTANCE; INTERMITTENT CHEMOTHERAPY; COMPLEX BACTEREMIA; INFECTION MODEL; HIV-INFECTION; TUBERCULOSIS; DISEASE; THERAPY; CLARITHROMYCIN;
D O I
10.1128/AAC.01355-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Ethambutol, together with a macrolide, is the backbone for treatment of disseminated Mycobacterium avium disease. However, at the standard dose of 15 mg/kg of body weight/day, ethambutol efficacy is limited. In addition, susceptibility breakpoints have consistently failed to predict clinical outcome. We performed dose-effect studies with extracellular M. avium as well as with bacilli within human macrophages. The maximal kill rate (E(max)) for ethambutol against extracellular bacilli was 5.54 log(10) CFU/ml, compared to 0.67 log(10) CFU/ml for intracellular M. avium, after 7 days of exposure. Thus, extracellular assays demonstrated high efficacy. We created a hollow-fiber system model of intracellular M. avium and performed microbial pharmacokinetic-pharmacodynamic studies using pharmacokinetics similar to those of ethambutol for humans. The E(max) in the systems was 0.79 log(10) CFU/ml with 7 days of daily therapy, so the kill rates approximated those encountered in patients treated with ethambutol monotherapy. Ratio of peak concentration to MIC (C(max)/MIC) was linked to microbial kill rate. The C(max)/MIC ratio needed to achieve the 90% effective concentration (EC(90)) in serum was 1.23, with a calculated intramacrophage C(max)/MIC ratio of 13. In 10,000 patient Monte Carlo simulations, doses of 15, 50, and 75 mg/kg achieved the EC90 in 35.50%, 76.81%, and 86.12% of patients, respectively. Therefore, ethambutol doses of >= 50 mg/kg twice a week would be predicted to be better than current doses of 15 mg/kg for treatment of disseminated M. avium disease. New susceptibility breakpoints and critical concentrations of 1 to 2 mg/liter were identified for the determination of ethambutol-resistant M. avium in Middle-brook broth. Given that the modal MIC of clinical isolates is around 2 mg/liter, most isolates should be considered ethambutol resistant.
引用
收藏
页码:1728 / 1733
页数:6
相关论文
共 45 条
[1]  
ALBERT RK, 1976, AM REV RESPIR DIS, V114, P699
[2]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[3]   Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci [J].
Ambrose, Paul G. ;
Meagher, Alison K. ;
Passarell, Julie A. ;
Van Wart, Scott A. ;
Cirincione, Brenda B. ;
Bhavnani, Sujata M. ;
Ellis-Grosse, Evelyn .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (02) :155-159
[4]   Monte Carlo simulation in the evaluation of susceptibility breakpoints: Predicting the future - Insights from the society of infectious diseases pharmacists [J].
Ambrose, PG .
PHARMACOTHERAPY, 2006, 26 (01) :129-134
[5]  
[Anonymous], ANTIMICROBIAL PHARMA
[6]   2 COMPARTMENT KINETIC-MODEL WITH MULTIPLE ARTIFICIAL CAPILLARY UNITS [J].
BLASER, J ;
STONE, BB ;
ZINNER, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :131-137
[7]   EFFICACY OF INTERMITTENT VERSUS CONTINUOUS ADMINISTRATION OF NETILMICIN IN A 2-COMPARTMENT INVITRO MODEL [J].
BLASER, J ;
STONE, BB ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (03) :343-349
[8]   Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection [J].
Chaisson, RE ;
Keiser, P ;
Pierce, M ;
Fessel, WJ ;
Ruskin, J ;
Lahart, C ;
Benson, CA ;
Meek, K ;
Siepman, N ;
Craft, JC .
AIDS, 1997, 11 (03) :311-317
[9]   Impact of opportunistic disease on survival in patients with HIV infection [J].
Chaisson, RE ;
Gallant, JE ;
Keruly, JC ;
Moore, RD .
AIDS, 1998, 12 (01) :29-33
[10]   INCIDENCE AND NATURAL-HISTORY OF MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
CHAISSON, RE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CREAGH, T .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (02) :285-289